AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29754267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and comparison groups
Number of subjects: 432
Study 29754267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (men)
Number of subjects: 432
Study 29754267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (women)
Number of subjects: 432
Study 28177703 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load (50% 1RM) explosive contractions (MLEC)
Number of subjects: 15
Study 28177703 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load (80% 1-repetition maximum (1RM)) explosive contractions (HLEC)
Number of subjects: 15
Study 28177703 — intervention group
Group type: COMPARATOR
Intervention: Heavy-load, controlled (2 s) (HLCC)
Number of subjects: 15
Study 28177703 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition × sex interaction for blood lactate changes
Number of subjects: 15
Study 26211765 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA in parenteral nutrition
Number of subjects: 47
Study 26211765 — intervention group
Group type: COMPARATOR
Intervention: Control (without omega-3 PUFA in parenteral nutrition)
Number of subjects: 47
Study 23205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone tablets 200 mg vaginally daily (Group A)
Number of subjects: 160
Study 23205864 — intervention group
Group type: COMPARATOR
Intervention: 100 mg progesterone intramuscular every third day (Group B)
Number of subjects: 160
Study 23205864 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (Group B)
Number of subjects: 160
Study 23205864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Group A)
Number of subjects: 160
Study 21999153 — intervention group
Group type: EXPERIMENTAL
Intervention: Taijiquan classes (n=76)
Number of subjects: 208
Study 21999153 — intervention group
Group type: COMPARATOR
Intervention: Special recreation (control group, n=132)
Number of subjects: 208
Study 18280415 — intervention group
Group type: EXPERIMENTAL
Intervention: Single sagittal radius femoral design
Number of subjects: 100
Study 18280415 — intervention group
Group type: COMPARATOR
Intervention: Multiradius femoral design
Number of subjects: 100
Study 17080540 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiong‐gui‐jiao‐ai‐tang (7.5 g/day)
Number of subjects: 72
Study 17080540 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 72
Study 14767417 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4.5 mg/kg)
Number of subjects: 10
Study 14767417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10954004 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nitrendipine or nifedipine)
Number of subjects: 50
Study 10954004 — intervention group
Group type: COMPARATOR
Intervention: No calcium antagonists
Number of subjects: 50
Study 8660034 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal energy content meals (1700 kcal)
Number of subjects: 28
Study 8660034 — intervention group
Group type: COMPARATOR
Intervention: Low energy content meals (260 kcal)
Number of subjects: 28
Study 1553052 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (orally administered)
Number of subjects: 100
Study 1553052 — intervention group
Group type: COMPARATOR
Intervention: Heparin calcium
Number of subjects: 100
Study 29032877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative instillation of 7.5mg of ropivacaine
Number of subjects: 72
Study 29032877 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (control)
Number of subjects: 72
Study 27297634 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 3084
Study 27297634 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 3084
Study 27297634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic or hypnotic drugs
Number of subjects: 3084
Study 27297634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported depression and anxiety
Number of subjects: 3084
Study 27297634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported depression with insomnia
Number of subjects: 3084
Study 24694335 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D3
Number of subjects: 644
Study 24694335 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3
Number of subjects: 644
Study 24694335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study 24694335 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors (SNPs in CYP2R1, IRF4, MC1R, CYP27B1, VDR, TYRP1, MCM6, HERC2)
Number of subjects: 644
Study 24694335 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including SNPs
Number of subjects: 644
Study 23341518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-only chemotherapy (doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin plus cyclophosphamide followed by CMF)
Number of subjects: 2009
Study 23341518 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy combining doxorubicin and docetaxel (doxorubicin plus docetaxel followed by CMF or doxorubicin followed by docetaxel followed by CMF)
Number of subjects: 2009
Study 23341518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-only chemotherapy
Number of subjects: 2009
Study 20595800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (10 to 40 mg/day for 18 months)
Number of subjects: 10
Study 18675295 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen Active Living Model (GALM) recruitment strategy
Number of subjects: 315
Study 18675295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of recruitment
Number of subjects: 315
Study 17141642 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen
Number of subjects: 40
Study 17141642 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) with zaltoprofen
Number of subjects: 40
Study 17141642 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) without zaltoprofen
Number of subjects: 40
Study 14682400 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (SexG), 6 group sessions
Number of subjects: 257
Study 14682400 — intervention group
Group type: COMPARATOR
Intervention: Control intervention, 6-session HIV educational program
Number of subjects: 257
Study 10876460 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 10876460 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 22
Study 8959150 — intervention group
Group type: EXPERIMENTAL
Intervention: MB‐Check system
Number of subjects: 1840
Study 8959150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactec‐460 system
Number of subjects: 1840
Study 8959150 — intervention group
Group type: COMPARATOR
Intervention: Lowenstein‐Jensen (LJ) medium
Number of subjects: 1840
Study 8959150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bactec and MB‐Check systems
Number of subjects: 1840
Study 1530193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza A (H3N2) virus vaccine
Number of subjects: 523
Study 4064565 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 50 ng min‐1 kg‐1 (high A)
Number of subjects: 7
Study 4064565 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 10 ng min‐1 kg‐1 (low A)
Number of subjects: 7
Study 4064565 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (saline: 154 mmol of NaCl/l) plus ascorbic acid, 1 mg/ml (control)
Number of subjects: 7
Study 31415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners reporting medium acceptance of intimate partner violence
Number of subjects: 0
Study 31415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partners reporting low acceptance of intimate partner violence
Number of subjects: 0
Study 31415040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender equality measured by decision making power
Number of subjects: 0
Study 30560721 — intervention group
Group type: EXPERIMENTAL
Intervention: Video lectures
Number of subjects: 205
Study 30560721 — intervention group
Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 205
Study 30560721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation of learning atmosphere, ability to concentrate, presence of other students, and acoustic intelligibility
Number of subjects: 205
Study 26582140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum combined with behavioral reduction counseling (BR)
Number of subjects: 517
Study 26582140 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral reduction counseling (BR)
Number of subjects: 517
Study 26582140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum without motivational interviewing (MI)
Number of subjects: 517
Study 24604409 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG gel in sugar cookies (40 g)
Number of subjects: 18
Study 24604409 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG gel in baked products (high and low moisture)
Number of subjects: 18
Study 24604409 — intervention group
Group type: COMPARATOR
Intervention: Industry standard stearic‐rich shortening
Number of subjects: 18
Study 22801836 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine
Number of subjects: 4
Study 22801836 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine
Number of subjects: 4
Study 20131296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV cyclophosphamide (50 mg/kg daily for 4 days)
Number of subjects: 51
Study 20131296 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (monthly IV cyclophosphamide at 750 mg/m2 for 6 months followed by quarterly IV cyclophosphamide for 2 years)
Number of subjects: 51
Study 18475047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin layer smears
Number of subjects: 3875
Study 18475047 — intervention group
Group type: COMPARATOR
Intervention: Conventional smears
Number of subjects: 3875
Study 15954952 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 60-65% in oxygen
Number of subjects: 26
Study 15954952 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg/kg/h
Number of subjects: 26
Study 12550813 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-force model
Number of subjects: 2
Study 12550813 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 2
Study 10624427 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable acrylic intraocular lens (IOL), n = 38
Number of subjects: 67
Study 10624427 — intervention group
Group type: COMPARATOR
Intervention: Rigid polymethyl-methacrylate (PMMA) IOL, n = 29
Number of subjects: 67
Study 10624427 — intervention group
Group type: COMPARATOR
Intervention: Age-matched normal subjects, n = 28
Number of subjects: 67
Study 8750406 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 20 mg BID
Number of subjects: 172
Study 8750406 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg BID
Number of subjects: 172
Study 8750406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 172
Study 2027977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 174
Study 2027977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 6799401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutro-Drip
Number of subjects: 40
Study 31618056 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the left primary motor cortex (A‐tDCS‐M1)
Number of subjects: 52
Study 31618056 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over Broca's area
Number of subjects: 52
Study 31618056 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 52
Study 28285641 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA mixture (40% leucine)
Number of subjects: 42
Study 28285641 — intervention group
Group type: COMPARATOR
Intervention: TAA mixture (balanced free EAAs and non-EAAs as present in whey protein)
Number of subjects: 42
Study 28285641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mixtures
Number of subjects: 42
Study 26669545 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive implants
Number of subjects: 106
Study 26669545 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 106
Study 25122437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E)
Number of subjects: 743
Study 25122437 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus placebo (B+P)
Number of subjects: 743
Study 25122437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E) in patients with EGFR mutation-positive NSCLC
Number of subjects: 743
Study 25122437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (B+E) in patients with KRAS wild-type disease
Number of subjects: 743
Study 22964325 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG 1064-nm laser treatment (8 sessions with a one-week interval)
Number of subjects: 33
Study 22964325 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG 1064-nm laser treatment (4 sessions with a one-week interval)
Number of subjects: 33
Study 19772185 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate with KCl (test product)
Number of subjects: 24
Study 19772185 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate with NaCl (reference product)
Number of subjects: 24
Study 17383650 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐PBS stent
Number of subjects: 0
Study 17383650 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 0
Study 17383650 — intervention group
Group type: COMPARATOR
Intervention: AR‐PBS and PBS
Number of subjects: 0
Study 15523488 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (86 mg/day) for 2 months (study 1)
Number of subjects: 25
Study 15523488 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (86 mg/day) for 3 months (study 2)
Number of subjects: 25
Study 15523488 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months (study 1)
Number of subjects: 25
Study 15523488 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month (study 2)
Number of subjects: 25
Study 15523488 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation
Number of subjects: 25
Study 11772475 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone medical maintenance (MMM)
Number of subjects: 73
Study 11772475 — intervention group
Group type: COMPARATOR
Intervention: Routine methadone treatment
Number of subjects: 73
Study 10543767 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 10 days
Number of subjects: 15
Study 8529853 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (i.v.; 10 mg)
Number of subjects: 48
Study 8529853 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (s.l.; 5-10 mg)
Number of subjects: 48
Study 2180591 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline maleate
Number of subjects: 17
Study 2180591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6244079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiation therapy and CCNU therapy (Group A: 26 cases)
Number of subjects: 103
Study 6244079 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU given orally every 6‐8 weeks (Group B: 27 cases)
Number of subjects: 103
Study 6244079 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy alone (Group C: 50 cases)
Number of subjects: 103
Study 30187910 — intervention group
Group type: EXPERIMENTAL
Intervention: GoldieBlox (packaged for girls)
Number of subjects: 61
Study 30187910 — intervention group
Group type: COMPARATOR
Intervention: BobbyBlox (packaged for boys)
Number of subjects: 61
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with VVs
Number of subjects: 408455
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlation analysis
Number of subjects: 408455
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 408455
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis
Number of subjects: 408455
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleiotropic effects of VVs-associated variants
Number of subjects: 408455
Study 30998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic overlap analysis
Number of subjects: 408455
Study 27826985 — intervention group
Group type: EXPERIMENTAL
Intervention: CRYO
Number of subjects: 153
Study 27826985 — intervention group
Group type: COMPARATOR
Intervention: RF
Number of subjects: 153
Study 25655663 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 409
Study 25655663 — intervention group
Group type: COMPARATOR
Intervention: Receipt of a brief message
Number of subjects: 409
Study 23479393 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg po preoperatively followed by 200 mg po every eight hours for two days
Number of subjects: 101
Study 23479393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 23479393 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 101
Study 21216197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg per day)
Number of subjects: 50
Study 21216197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21216197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 50
Study 19135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=184)
Number of subjects: 369
Study 19135281 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=185)
Number of subjects: 369
Study 17316648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine (5-mL uterine instillation of 2% lidocaine) plus buccal misoprostol (200-microg tablet)
Number of subjects: 126
Study 17316648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution) plus buccal misoprostol (200-microg tablet)
Number of subjects: 126
Study 15792015 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibovitmama supplementation
Number of subjects: 0
Study 15792015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11099427 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pentobarbital (mean dose 3.75 ± 1.10 mg/kg)
Number of subjects: 55
Study 11099427 — intervention group
Group type: COMPARATOR
Intervention: IV midazolam (mean dose 0.2 ± 0.03 mg/kg)
Number of subjects: 55
Study 9768320 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decongestion
Number of subjects: 105
Study 9768320 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator
Number of subjects: 105
Study 1363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 160
Study 1363727 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 160
Study 6499702 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866
Study 6499702 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 30698279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 adjusted to maintain serum 25(OH)D above 30 ng/mL
Number of subjects: 260
Study 30698279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 29615123 — intervention group
Group type: EXPERIMENTAL
Intervention: EU EXPEDITION patients (n = 133)
Number of subjects: 734
Study 29615123 — intervention group
Group type: COMPARATOR
Intervention: GERAS patients (n = 417)
Number of subjects: 734
Study 29615123 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analysis comparing EU/NA EXPEDITION patients with GERAS patients
Number of subjects: 734
Study 28042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy for poststroke urinary incontinence (10 sessions)
Number of subjects: 40
Study 28042304 — intervention group
Group type: COMPARATOR
Intervention: Sham therapies (10 sessions)
Number of subjects: 40
Study 28042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy
Number of subjects: 40
Study 28042304 — intervention group
Group type: COMPARATOR
Intervention: Sham therapies
Number of subjects: 40
Study 25887891 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention (cognitive and self-regulation processes)
Number of subjects: 1349
Study 25887891 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus intervention (cognitive, self-regulation processes, and environmental-level factors)
Number of subjects: 1349
Study 25887891 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic nutrition information)
Number of subjects: 1349
Study 22001552 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 665
Study 22001552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 665
Study 22001552 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 665
Study 22001552 — intervention group
Group type: COMPARATOR
Intervention: Participants with HD
Number of subjects: 665
Study 22001552 — intervention group
Group type: COMPARATOR
Intervention: Participants without HD
Number of subjects: 665
Study 20021517 — intervention group
Group type: EXPERIMENTAL
Intervention: CT overlay (group 1, n = 38)
Number of subjects: 68
Study 20021517 — intervention group
Group type: COMPARATOR
Intervention: CartoMerge (group 2, n = 30)
Number of subjects: 68
Study 20021517 — intervention group
Group type: EXPERIMENTAL
Intervention: CT overlay (group 1)
Number of subjects: 68
Study 20021517 — intervention group
Group type: COMPARATOR
Intervention: CartoMerge (group 2)
Number of subjects: 68